Celanese Corporation heads into the post-earnings session with a dramatically cleaner short book, a guidance beat that caught Wall Street off-guard, and options traders only now walking back the defensive hedges they had built ahead of the print.
The week's defining move was in short interest. Shorts slashed their exposure by nearly a quarter over the past five trading days — SI % FF fell from roughly 8.1% to 6.2% as the company delivered Q1 results after the close on Tuesday. The stock gained 6.7% on the week to close at $69.01, and the covering was largely pre-positioned: the sharpest unwind happened in the days immediately before and after the print, with shares short dropping from a late-April high near 8.9 million to around 6.8 million by Wednesday. That April 27 spike — when SI briefly touched what now looks like the week's crowded extreme — proved to be the peak. Shorts that waited too long to cover got squeezed into strength.
The borrow market tells a complementary story. Availability remains loose, keeping this firmly out of squeeze territory. The lending environment is comfortable, with cost to borrow running at just 0.42% annualised — elevated roughly 35% over the past month but still deep in cheap-and-easy territory. The short score of 42.1 sits well below the levels that signal stressed positioning. None of this looks like a forced unwind; it looks like a deliberate exit into positive newsflow.
Options traders were clearly braced for a difficult print. The put/call ratio jumped to 0.80 on Tuesday, more than 2.5 standard deviations above its 20-day average of 0.65 — the most defensive reading in months and well outside normal hedging activity. With Q2 guidance landing materially above consensus (the company guided adjusted EPS of $2.00–$2.40 against a $1.52 estimate), those puts are likely to decay quickly. Alongside the earnings beat on revenue at $2.337 billion versus a $2.326 billion estimate, management also announced a restructuring of its nylon operations — closing the Singapore Sakra facility and optimising North American Nylon 6,6 sites — signalling a sharper focus on capital efficiency.
The Street has been moving in one direction for weeks: upward. Virtually every recent target-price revision has been a raise. Morgan Stanley lifted its target to $72 from $50 while holding Equal-Weight. Mizuho moved to $65 from $58, also at Neutral. BofA Securities, already constructive with a Buy, raised to $75. Citigroup sits at $84. The average consensus target of around $72 now sits just above Wednesday's close, leaving modest implied upside even after the week's rally — which means bulls need the guidance to be achievable rather than aspirational. The bull case centres on an automotive and electronics recovery driving acetic acid demand and pushing EBITDA toward $2.5 billion. The bear case is grimmer: acetyl product demand in the Western Hemisphere remains near two-decade lows, and China and European automotive exposure remains a drag.
Valuation multiples reflect the improvement. The EV/EBITDA sits around 9.3x, down roughly 0.35x over the past month as the earnings trajectory firmed. The PE of 11.5x and the price-to-book of 1.5x are undemanding for a specialty chemicals franchise if the second-half EPS targets — management's stated goal is $3 per share in the back half of 2026 — prove credible. The EPS momentum factor score, ranked in the 86th percentile on a 30-day basis, suggests estimate revisions have been running decisively in the right direction.
Closely correlated peers had a broadly positive week. DOW gained 7.3%, OLN added 7.3%, and LYB rose 8.8%. The notable outlier was WLK, which fell 5% on the week and dropped another 8.8% on Wednesday alone — a reminder that the sector's recovery is uneven. CE's outperformance against that backdrop is modest but real.
The next reference point is the formal Q1 earnings call transcript already in the market, along with whatever colour management provided on tariff exposure and the nylon restructuring timeline. The $3 second-half EPS target is now the number the Street will test every quarter.
See the live data behind this article on ORTEX.
Open CE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
